Ousia ['usja], from Greek; "essence"-Ousia Pharma arose from a unique discovery in academia and was quickly transformed into a biotechnology company. Ousia Pharma is paving the way for novel therapeutic strategies using peptide-drug-conjugates for the benefit of patients with metabolic and cognitive disorders.
Who are we?
Ousia Pharma ApS is a Danish biotech start-up focused on the development of novel peptide-drug conjugates for the treatment of cognitive disorders and metabolic diseases. We utilize a targeting approach in which peptides are used to deliver modulators of synaptic plasticity to the brain.
Board of Directors
We are dedicated to developing effective and safe pharmacotherapies to improve the health and lives of people living with metabolic and cognitive disorders